

Prematurely ended - Statement

EudraCT number: 2015-005715-32

Full title of the study: SOdium-glucose CO-transporter inhibition in patients with Type 2 Diabetes and Ischemic Heart Failure (SOCODIHF)

Sponsor: Karolinska Institutet

Contact person: lars.ryden@ki.se

Product: Empagliflozin (Jardiance™)

Date of the early termination of the trial: 2019-04-03

Statement on discontinuation of the study: Study terminated because of difficulties of recruiting patients. Only seven patients were recruited, no analyzes were carried out.

Sofie Possmark
Coordinator
Compliance & Data Office
Research Support Office
Karolinska Institutet
Sweden